Related content

Intranasal Treatment with a Recombinant Hypoallergenic Derivative of the Major Birch Pollen Allergen Bet v 1 Prevents Allergic Sensitization and Airway Inflammation in Mice

By  

International Archives of Allergy and Immunology, Vol. 126, Iss. 1, 2001-10 ,pp. : 68-77

Karger

Access to resources Recommend Favorite

Characterization of a Hypoallergenic Recombinant Bet v 1 Variant as a Candidate for Allergen-Specific Immunotherapy

By  

International Archives of Allergy and Immunology, Vol. 145, Iss. 3, 2007-10 ,pp. : 193-206

Karger

Access to resources Recommend Favorite

Cytokine and Antibody Responses in Birch-Pollen-Allergic Patients Treated with Genetically Modified Derivatives of the Major Birch Pollen Allergen Bet v 1

By  

International Archives of Allergy and Immunology, Vol. 138, Iss. 1, 2005-09 ,pp. : 59-66

Karger

Access to resources Recommend Favorite

A Model System to Study the Environment-Dependent Expression of the Bet v 1a Gene Encoding the Major Birch Pollen Allergen

By  

International Archives of Allergy and Immunology, Vol. 134, Iss. 1, 2004-05 ,pp. : 1-9

Karger

Access to resources Recommend Favorite

Expression of a Human IgG4 Antibody, BAB2, with Specificity for the Major Birch Pollen Allergen, Bet v 1 in Escherichia coli: Recombinant BAB2 Fabs Enhance the Allergic Reaction

By  

International Archives of Allergy and Immunology, Vol. 118, Iss. 2-4, 1999-04 ,pp. : 190-192

Karger

Access to resources Recommend Favorite